|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/11/22 Oncocyte Corp. 10-K 12/31/21 90:10M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.76M
2: EX-4.11 Instrument Defining the Rights of Security Holders HTML 27K
3: EX-10.43 Material Contract HTML 236K
4: EX-21 Subsidiaries List HTML 26K
5: EX-23.1 Consent of Independent Registered Public HTML 25K
Accounting Firm
6: EX-23.2 Consent of Independent Registered Public HTML 25K
Accounting Firm
7: EX-31.1 Certification -- §302 - SOA'02 HTML 32K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
15: R1 Cover HTML 97K
16: R2 Consolidated Balance Sheets HTML 139K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 43K
18: R4 Consolidated Statements of Operations HTML 104K
19: R5 Consolidated Statements of Comprehensive Loss HTML 43K
20: R6 Consolidated Statements of Shareholders' Equity HTML 97K
21: R7 Consolidated Statements of Cash Flows HTML 156K
22: R8 Organization, Description of the Business and HTML 53K
Liquidity
23: R9 Basis of Presentation and Summary of Significant HTML 153K
Accounting Policies
24: R10 Business Combinations HTML 224K
25: R11 Goodwill and Intangible Assets, net HTML 54K
26: R12 Shareholders? Equity HTML 49K
27: R13 Stock-Based Compensation HTML 134K
28: R14 Disaggregation of Revenues and Concentration Risk HTML 67K
29: R15 Income Taxes HTML 77K
30: R16 Right-of-use Assets, Machinery and Equipment, Net HTML 37K
and Construction in Progress
31: R17 Commitments and Contingencies HTML 89K
32: R18 Related Party Transactions HTML 45K
33: R19 Loan Payable to Silicon Valley Bank HTML 47K
34: R20 Quarterly Financial Data (Unaudited) HTML 67K
35: R21 Subsequent Events HTML 42K
36: R22 Basis of Presentation and Summary of Significant HTML 225K
Accounting Policies (Policies)
37: R23 Basis of Presentation and Summary of Significant HTML 48K
Accounting Policies (Tables)
38: R24 Business Combinations (Tables) HTML 131K
39: R25 Goodwill and Intangible Assets, net (Tables) HTML 54K
40: R26 Stock-Based Compensation (Tables) HTML 115K
41: R27 Disaggregation of Revenues and Concentration Risk HTML 72K
(Tables)
42: R28 Income Taxes (Tables) HTML 58K
43: R29 Right-of-use Assets, Machinery and Equipment, Net HTML 35K
and Construction in Progress (Tables)
44: R30 Commitments and Contingencies (Tables) HTML 62K
45: R31 Quarterly Financial Data (Unaudited) (Tables) HTML 65K
46: R32 Organization, Description of the Business and HTML 82K
Liquidity (Details Narrative)
47: R33 Schedule of Prepaid Expenses and Other Current HTML 38K
Assets (Details)
48: R34 Schedule of Reconciliation of Cash, Cash HTML 34K
Equivalents, and Restricted Cash (Details)
49: R35 Schedule of Common Stock Equivalents Excluded from HTML 33K
Computation of Diluted Net Loss Per Share of
Common Stock (Details)
50: R36 Basis of Presentation and Summary of Significant HTML 75K
Accounting Policies (Details Narrative)
51: R37 Schedule of Fair Value of Aggregate Merger HTML 49K
Consideration (Details)
52: R38 Schedule of Fair Value of Aggregate Merger HTML 33K
Consideration (Details) (Parenthetical)
53: R39 Schedule of Intangible Assets Acquired and HTML 65K
Liabilities Assumed (Details)
54: R40 Schedule of Identifiable Intangible Assets and HTML 34K
Estimated Useful Life (Details)
55: R41 Schedule of Fair Value of Contingent Consideration HTML 42K
Liability (Details)
56: R42 Schedule of Contingent Consideration, Measured at HTML 43K
Fair Value (Details)
57: R43 Schedule of Acquisition Intangible Assets HTML 44K
(Details)
58: R44 Summary of Acquisition Intangible Assets (Details) HTML 29K
(Parenthetical)
59: R45 Schedule of Condensed Statement of Operations HTML 49K
(Details)
60: R46 Business Combinations (Details Narrative) HTML 223K
61: R47 Schedule of Goodwill and Intangible Assets HTML 58K
(Details)
62: R48 Schedule of Intangible Assets Future Amortization HTML 41K
Expense (Details)
63: R49 Shareholders? Equity (Details Narrative) HTML 79K
64: R50 Summary of Stock Option Activity (Details) HTML 101K
65: R51 Schedule of Stock Options Outstanding, Vested and HTML 50K
Exercisable (Details)
66: R52 Summary of Stock-based Compensation Expense HTML 39K
(Details)
67: R53 Schedule of Assumptions Used to Calculate Fair HTML 35K
Value of Stock Options (Details)
68: R54 Stock-Based Compensation (Details Narrative) HTML 76K
69: R55 Schedule of Consolidated Revenues Attributable to HTML 39K
Products or Services (Details)
70: R56 Schedule of Consolidated Revenues Generated by HTML 46K
Unaffiliated Customers (Details)
71: R57 Schedule of Percentage of Consolidated Revenues HTML 38K
Attributable to Geographical Locations (Details)
72: R58 Schedule of Percentage of Total Consolidated HTML 37K
Accounts Receivables (Details)
73: R59 Schedule of Components of Deferred Tax Assets and HTML 56K
Liabilities (Details)
74: R60 Schedule of Income Tax Reconciliation (Details) HTML 45K
75: R61 Schedule of Unrecognized Tax Benefit (Details) HTML 35K
76: R62 Income Taxes (Details Narrative) HTML 80K
77: R63 Schedule of Right-of-use Assets, Machinery and HTML 41K
Equipment, Net, and Construction in Progress
(Details)
78: R64 Right-of-use Assets, Machinery and Equipment, Net HTML 28K
and Construction in Progress (Details Narrative)
79: R65 Schedule of Supplemental Cash Flow Information HTML 35K
Related to Operating and Financing Lease (Details)
80: R66 Schedule of Supplemental Balance Sheet Information HTML 60K
Related to Operating and Financing Leases
(Details)
81: R67 Schedule of Future Minimum Lease Commitments for HTML 65K
Operating and Financing Leases (Details)
82: R68 Commitments and Contingencies (Details Narrative) HTML 66K
83: R69 Related Party Transactions (Details Narrative) HTML 70K
84: R70 Loan Payable to Silicon Valley Bank (Details HTML 72K
Narrative)
85: R71 Schedule of Quarterly Financial Information HTML 79K
(Details)
88: XML IDEA XML File -- Filing Summary XML 161K
86: XML XBRL Instance -- form10-k_htm XML 2.12M
87: EXCEL IDEA Workbook of Financial Reports XLSX 145K
11: EX-101.CAL Inline XBRL Taxonomy Extension Calculation XML 220K
Linkbase Document -- ocx-20211231_cal
12: EX-101.DEF Inline XBRL Taxonomy Extension Definition Linkbase XML 850K
Document -- ocx-20211231_def
13: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 1.55M
Document -- ocx-20211231_lab
14: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 1.19M
Linkbase Document -- ocx-20211231_pre
10: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 238K
ocx-20211231
89: JSON XBRL Instance as JSON Data -- MetaLinks 461± 647K
90: ZIP XBRL Zipped Folder -- 0001493152-22-006677-xbrl Zip 520K
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in Amendment No. 2 to Registration Statement on Form S-1 (No. 333-213810), Registration Statements on Form S-3 (Nos. 333-220769, 333-231980, 333-240207, 333-252765, 333-256650 and 333-257905) and in Registration Statements on Form S-8 (Nos. 333-219109, 333-208935, 333-227118, 333-232773 and 333-257740) of OncoCyte Corporation of our report dated March 19, 2021 relating to the consolidated financial statements of OncoCyte Corporation as of and for the year ended December 31, 2021, which appears in this Annual Report on Form 10-K.
/s/ OUM & CO. LLP
San Francisco, California
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/11/22 | |||
| For Period end: | 12/31/21 | 10-K/A | ||
| 3/19/21 | 10-K, 4 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/12/23 Oncocyte Corp. 10-K 12/31/22 94:11M M2 Compliance LLC/FA 4/06/23 Oncocyte Corp. 424B5 1:307K M2 Compliance LLC/FA 5/12/22 Oncocyte Corp. 10-Q 3/31/22 78:7.5M M2 Compliance LLC/FA 5/02/22 Oncocyte Corp. 10-K/A 12/31/21 12:649K M2 Compliance LLC/FA 4/18/22 Oncocyte Corp. 424B5 1:384K M2 Compliance LLC/FA 4/15/22 Oncocyte Corp. 424B5 1:440K M2 Compliance LLC/FA 4/13/22 Oncocyte Corp. 424B5 1:442K M2 Compliance LLC/FA |